Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fasting-Based Dietary Interventions in Cancer Patients and Survivors: A Scoping Review.

Nutrients·2026
Same author

A Prolonged Nightly Fasting Plus Telehealth Coaching Intervention (PNF+) for Men on Androgen Deprivation Therapy for PCa: A Pilot Feasibility Randomized Controlled Trial.

Nutrients·2026
Same author

Urologic Device Innovation and Trends: An Analysis of Food and Drug Administration Approvals From 1990 to 2023.

Urology practice·2026
Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Metastatic castrate-resistant prostate cancer to the penis resulting in malignant priapism and urethral obstruction.

Urology case reports·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate Cancer.

Carlos Jesus Perez Kerkvliet1, Joon Yau Leong1, Rasheed A M Thompson1

  • 1Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Cancers
|July 12, 2025
PubMed
Summary
This summary is machine-generated.

Neoadjuvant androgen deprivation therapy (ADT) before prostatectomy may reduce surgical complexity for high-risk prostate cancer. Current evidence does not support its use for improved survival, but new trials are exploring advanced therapies.

Keywords:
cancerchemotherapyneoadjuvantprostateprostatectomy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Related Experiment Videos

Last Updated: Sep 16, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Area of Science:

  • Oncology
  • Urology
  • Medical Research

Background:

  • Current prostate cancer guidelines recommend radical prostatectomy (RP) or radiation with androgen deprivation therapy (ADT) for unfavorable intermediate- to high-risk disease.
  • Neoadjuvant ADT prior to RP is being investigated for potential benefits in localized prostate cancer.
  • Past studies suggest neoadjuvant ADT may decrease surgical complexity and improve pathological outcomes, but without proven survival benefits.

Purpose of the Study:

  • To review the current literature on neoadjuvant therapy for clinically localized prostate cancer.
  • To explore ongoing research into novel agents and strategies for neoadjuvant treatment in high-risk prostate cancer patients undergoing RP.

Main Methods:

  • Narrative review of recent scientific literature.
  • Analysis of ongoing clinical trials investigating neoadjuvant therapies.

Main Results:

  • Neoadjuvant ADT has shown potential for reducing surgical complexity, pathologic downstaging, and positive margin rates.
  • Existing trials have not demonstrated improved cancer progression or survival rates with neoadjuvant ADT.
  • Interest persists in expanding ADT use to localized disease, with ongoing trials evaluating new agents.

Conclusions:

  • Neoadjuvant ADT is not currently recommended for surgical prostate cancer patients due to lack of survival benefit.
  • Ongoing trials with novel agents like enzalutamide, darolutamide, radiopharmaceuticals, and PARP inhibitors aim to establish long-term survival benefits.
  • Further research is crucial to determine the role of neoadjuvant therapy in improving outcomes for high-risk localized prostate cancer.